Vitrolife AB (VITR) AI Stock Analysis

• Market Cap: kr17.68B
• Dividend Yield: 0.8%
• Average Volume (3M): 92.36K
• Price to Earnings (P/E): 40.1
• Beta (1Y): 0.51
• Revenue Growth: -1.29%
• EPS Growth: N/A
• Country: SE
• Employees: 1,150
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Devices
• EPS (TTM): 0.75
• Shares Outstanding: 135,447,190
• 10 Day Avg. Volume: 105,869
• 30 Day Avg. Volume: 92,365
• PEG Ratio: -0.50
• Price to Book (P/B): 2.13
• Price to Sales (P/S): 8.07
• P/FCF Ratio: 32.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: kr167.00 ▲(25.56% Upside)

Vitrolife AB's overall stock score of 71 reflects a balanced financial performance with strong profitability and cash flow generation, despite challenges in revenue growth. Technical indicators show positive momentum, supporting the stock's upward trend. However, a high P/E ratio suggests the stock is expensive, which could limit upside potential. The earnings call highlights strategic investments and regional growth, particularly in the Americas, which are positive for future prospects.

Positive Factors

Strong Cash Flow Generation

Robust cash flow generation enhances Vitrolife's financial flexibility, enabling strategic investments and resilience against economic fluctuations.

Solid Balance Sheet

A strong balance sheet with low leverage provides Vitrolife with stability and the ability to invest in growth opportunities without financial strain.

Growth in Americas

Significant growth in the Americas reflects successful market penetration and positions Vitrolife for continued expansion in a key region.

Negative Factors

Revenue Growth Challenges

Declining revenue growth poses a risk to long-term profitability and market competitiveness, necessitating strategic initiatives to reverse the trend.

Currency Impact

Adverse currency impacts can erode profitability and create volatility in financial results, challenging Vitrolife's margin sustainability.

Increased Operating Expenses

Rising operating expenses, while strategic, could pressure margins if not matched by corresponding revenue growth, impacting long-term profitability.

Vitrolife AB Business Overview & Revenue Model

Company Description

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.

How the Company Makes Money

Vitrolife generates revenue primarily through the sale of its products and services to fertility clinics and hospitals worldwide. Its key revenue streams include the sale of culture media, cryopreservation products, and IVF-related equipment. The company also provides training and support services to its customers, enhancing their operational efficiency and effectiveness in assisted reproduction. Significant partnerships with healthcare institutions and participation in global fertility conferences contribute to its earnings by expanding its market reach and establishing Vitrolife as a trusted brand in the reproductive health sector.

Vitrolife AB Financial Statement Overview

Summary

Vitrolife AB shows strong profitability with healthy margins, but recent revenue and free cash flow declines pose potential risks. The balance sheet is robust with low leverage and strong equity, providing financial stability. While cash flow metrics are generally positive, the decline in free cash flow growth warrants attention.

Income Statement

Vitrolife AB's income statement shows a mixed performance. The TTM data indicates a slight decline in revenue growth rate at -1.94%, which is concerning. However, the company maintains a healthy gross profit margin of 58.83% and a net profit margin of 12.86%, reflecting stable profitability. The EBIT and EBITDA margins are also robust at 19.36% and 25.60% respectively, although they have decreased compared to the previous year. Overall, the company demonstrates strong profitability, but the recent revenue decline is a potential risk.

Balance Sheet

Vitrolife AB's balance sheet is solid with a low debt-to-equity ratio of 0.15, indicating conservative leverage. The return on equity (ROE) is modest at 3.42%, suggesting room for improvement in generating returns for shareholders. The equity ratio is strong, with stockholders' equity comprising a significant portion of total assets, indicating financial stability. Overall, the balance sheet reflects a stable financial position with low leverage and good equity strength.

Cash Flow

The cash flow statement reveals some challenges for Vitrolife AB. The free cash flow growth rate is negative at -6.63%, indicating a decline in cash generation. However, the operating cash flow to net income ratio is healthy at 1.08, suggesting efficient cash conversion from earnings. The free cash flow to net income ratio is also strong at 0.93, indicating good cash flow relative to profits. Despite the decline in free cash flow growth, the company maintains a solid cash flow position relative to its net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.51B	3.61B	3.51B	3.23B	1.68B	1.25B
Gross Profit	2.00B	2.14B	1.98B	1.78B	1.05B	767.67M
EBITDA	873.00M	783.00M	-3.19B	977.00M	579.60M	438.65M
Net Income	441.00M	513.00M	-3.85B	394.00M	341.00M	286.85M
Balance Sheet
Total Assets	16.85B	17.45B	16.33B	20.55B	19.43B	2.31B
Cash, Cash Equivalents and Short-Term Investments	1.11B	1.14B	861.00M	578.00M	630.09M	973.57M
Total Debt	2.00B	2.09B	2.09B	2.23B	2.48B	62.40M
Total Liabilities	3.55B	3.81B	3.61B	3.81B	4.09B	288.07M
Stockholders Equity	13.30B	13.64B	12.72B	16.74B	15.32B	2.01B
Cash Flow
Free Cash Flow	687.00M	907.00M	638.00M	549.00M	321.86M	336.36M
Operating Cash Flow	743.00M	907.00M	757.00M	636.00M	384.31M	356.45M
Investing Cash Flow	-303.00M	-377.00M	-124.00M	-144.00M	-6.52B	-20.22M
Financing Cash Flow	-204.00M	-286.00M	-300.00M	-582.00M	5.75B	-26.61M

Vitrolife AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 133.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VITR, the sentiment is Negative. The current price of 133 is below the 20-day moving average (MA) of 135.65, below the 50-day MA of 140.96, and below the 200-day MA of 144.01, indicating a bearish trend. The MACD of -1.97 indicates Positive momentum. The RSI at 40.95 is Neutral, neither overbought nor oversold. The STOCH value of 50.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VITR.

Vitrolife AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VITR	71 Outperform	kr17.68B	40.07	3.34%	0.80%	-1.29%	―
CEVI	68 Neutral	kr3.84B	25.36	17.89%	1.61%	1.53%	0.79%
GETI.B	66 Neutral	kr61.12B	29.76	6.91%	2.16%	6.74%	21.40%
XVIVO	63 Neutral	kr6.14B	205.33	1.32%	―	8.39%	-85.36%
SECT.B	58 Neutral	kr46.59B	71.18	38.97%	0.43%	10.08%	68.12%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
BICO	50 Neutral	kr1.38B	-2.03	-57.26%	―	-23.24%	45.32%

Vitrolife AB Corporate Events

Vitrolife Restructures Genetic Services for Strategic Growth

Vitrolife AB announced a restructuring program for its genetic services business, aiming for annual savings of SEK 65 million by the end of Q3 2026. The program involves discontinuing certain genetic test lines and exiting low-profit markets, impacting 6% of the workforce and resulting in a SEK 5.4 billion goodwill impairment related to the Igenomix acquisition.

The most recent analyst rating on (SE:VITR) stock is a Buy with a SEK167.00 price target. To see the full list of analyst forecasts on Vitrolife AB stock, see the SE:VITR Stock Forecast page.

Vitrolife AB Reports Mixed Q3 2025 Results Amid Currency Challenges

Vitrolife AB reported a mixed financial performance for Q3 2025, with a 3% growth in sales in local currencies but a 4% decrease in SEK due to currency impacts. The company saw significant growth in the Americas and in its technologies and consumables product groups, despite a challenging currency environment affecting margins. The company also signed a EUR 300 million loan agreement to refinance existing debt and support general corporate purposes, indicating strategic financial management amidst currency challenges.

The most recent analyst rating on (SE:VITR) stock is a Hold with a SEK147.00 price target. To see the full list of analyst forecasts on Vitrolife AB stock, see the SE:VITR Stock Forecast page.